TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prophylaxis Gastric Variceal Bleed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with GOV2 without esophageal varix or IGV1, who had bled from GV were included~Exclusion Criteria:~* Presence of esophageal varix~* GOV2 with GOV1; contraindications to beta-blocker therapy and cyanoacrylate injection~* Prior injection of cyanoacrylate or sclerotherapy for GV or GV ligation, transjugular intrahepatic portosystemic shunt, balloon-occluded retrograde transvenous obliteration, balloon-occluded endoscopic injection sclerotherapy of GV, shunt operation for prevention of rebleeding from GV~* Patients already on beta-blocker or nitrates~* Undetermined origin of bleeding from esophageal varix or gastric varix~* Hepatic encephalopathy grade III/IV~* Hepatorenal syndrome~* Hepatocellular carcinoma~* Presence of deep jaundice (serum bilirubin \> 10 mg/dl)~* Uremia~* Cerebrovascular accident~* Cardiorespiratory failure~* Pregnancy or patients not giving informed consent for endoscopic procedures

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1. Endoscopic Cyanoacrylate injection (Type: ACTIVE_COMPARATOR): Endoscopic Cyanoacrylate injection in the gastric varix
- 2. Beta-blocker (Type: PLACEBO_COMPARATOR): Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Have completed two doses of Sinopharm, AstraZeneca or Sputnik vaccines with the recommended schedule 6 months prior to the date of enrolment~2. Willing and able to give written informed consent~3. Aged 18 years or above~4. Willing to complete the follow-up requirements of the study~Exclusion Criteria:~1. Received 3 doses of COVID-19 vaccine~2. Received 2 doses of COVID-19 less than 6 months prior to the start of the trial~3. Currently on immunosuppressive medication or anti-cancer chemotherapy~4. HIV infection~5. Congenital immune deficiency syndrome~6. Has received immunoglobulin or other blood products in the 3 months prior to vaccination~7. Study staff and their relatives~8. Have a history of a severe allergic reaction to any COVID-19 vaccines or have a medical exception to receiving further COVID-19 vaccines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AstraZeneca (ChAdOx1-S, or Vaxzevria®) - Standard Pfizer-BioNTech booster group (Type: ACTIVE_COMPARATOR): Previously received two doses of AstraZeneca as primary COVID-19 vaccine
- AstraZeneca (ChAdOx1-S, or Vaxzevria®) - Fractional Pfizer-BioNTech booster group (Type: EXPERIMENTAL): Previously received two doses of AstraZeneca as primary COVID-19 vaccine~.
- Sinopharm (BBIBP-CorV®)- Standard Pfizer-BioNTech booster group (Type: ACTIVE_COMPARATOR): Previously received two doses of Sinopharm as primary COVID-19 vaccine
- Sinopharm (BBIBP-CorV®)- Fractional Pfizer-BioNTech booster group (Type: EXPERIMENTAL): Previously received two doses of Sinopharm as primary COVID-19 vaccine
- Sputnik V (Gam-COVID-Vac®)- Standard Pfizer-BioNTech booster group (Type: ACTIVE_COMPARATOR): Previously received two doses of Sputnik as primary COVID-19 vaccine
- Sputnik V (Gam-COVID-Vac®)- Fractional Pfizer-BioNTech booster group (Type: EXPERIMENTAL): Previously received two doses of Sputnik as primary COVID-19 vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Aims 1 and 2:~* File a new accepted State Fund claim~* Fill at least one opioid prescription, paid for by workers' compensation, during the first 6 weeks after date of injury~Aim 3 key informants~* Policy makers and stakeholders who were involved in the creation and implementation of the Washington or Ohio opioid review program.~Aim 3 individual in-depth interviews~* Providers that had at least one patient whose opioid prescriptions paid for through workers' compensation had been reviewed in accordance with the state's opioid review program.~* Patients that had an opioid prescription for at least 6 weeks paid for by workers' compensation or whose prescription payments have been reviewed in accordance with the state's opioid review program.~Exclusion Criteria (Aims 1 and 2):~* Under 18 years of age~* Current cancer diagnosis~* Surveys only: do not speak English or Spanish, physically or mentally incapable of completing the survey, incarcerated, deceased

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Washington (Type: None): Workers in the Washington Department of Labor and Industries state fund insurance system.
- Ohio (Type: None): Workers in the Ohio Bureau of Workers' Compensation state fund insurance system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* chronic HCV infection~* HCV genotype 2/3 infection~* active injection drug use (within 24 weeks prior to consent) or currently receiving opiate substitution therapy~* compensated liver disease~* negative pregnancy test (within 24 hours of first dose of study medication)~* effective contraception for the duration of the study~* written informed consent~Exclusion Criteria:~* previous interferon or ribavirin therapy~* investigation drug use in the 6 weeks prior to first dose of study medication~* infection with HCV genotypes other than 2/3~* HIV infection~* HBV infection~* ongoing severe psychiatric disease~* frequent drug use that is judged by the treating physician to compromise treatment safety~* standard clinical and medical exclusions for treatment with pegylated interferon alfa 2b and ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Treatment Duration (24 weeks) (Type: ACTIVE_COMPARATOR): Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
- Shortened Treatment Duration (12 Weeks) (Type: EXPERIMENTAL): Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 65 years old who are healthy or have co-morbidities~* Individuals who or whose legal representative(s) have voluntarily given written consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry~* Ability to attend all scheduled visits and to comply with study procedures including diary card completion and follow-up~Exclusion Criteria:~* History of behavioral or cognitive impairment or psychiatric condition~* Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study~* Abnormal function of the immune system~* Receipt of any influenza vaccine within 6 months prior to enrollment in this study, or plan to receive influenza vaccine prior to the Day 22 blood collection~* Any other clinical condition that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study~Additional eligibility criteria may be discussed by contacting the site.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- aQIV (Type: EXPERIMENTAL): MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
- aTIV-1 (Type: EXPERIMENTAL): Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
- aTIV-2 (Type: EXPERIMENTAL): MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of stable plaque-type psoriasis affecting 2% to 10% of the subject's body surface area~* Psoriasis of a severity that is appropriate for treatment with topical therapy; PGA of at least 3 (moderate) at baseline; PSS of at least 7, and with no individual symptom score (erythema, induration, or scaling) less than 2~* Subject must sign the IRB approved informed consent and agree to follow dosing instructions and complete required clinic visits.~Exclusion Criteria:~* Pregnant or nursing females~* Systemic corticosteroids, methotrexate, cyclosporine, systemic retinoids, prolonged sun exposure or ultraviolet light therapy within 4 weeks of dosing~* Topical corticosteroids, retinoids, calcipotriene, coal tar, anthralin, or any other treatment indicated for psoriasis within 2 weeks of dosing~* Untreated bacterial, tubercular, fungal or any viral lesion of the skin~* Biologic agents/monoclonal antibodies in the last 6 months~* Currently using lithium or plaquenil~* Currently using a beta-blocking medication or thiazide diuretic and the dose has not been stabilized for at least 6 months~* History of hypercalcemia or evidence of vitamin D toxicity~* Current or history of melanoma skin cancer in the past 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease~Exclusion Criteria:~* Not taking a dopamine agonist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* people who receive colonoscopy~* aged : 18-80~* people who sign the consent~Exclusion Criteria:~* those aged over 80 years~* the disabled~* intestinal obstruction~* severe constipation~* previous history of bowel resection~* liver cirrhosis~* heart failure or ischemic heart disease within 6 months~* inflammatory bowel disease~* pregnant women~* severe renal insufficiency~* people who refuse to sign the consent

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Oral sulfate solution (OSS) (Type: EXPERIMENTAL): oral sulfate solution (OSS)
- 2-L PEG/Asc (Type: ACTIVE_COMPARATOR): low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age 18 and over diagnosed with RLS/WED by a board certified sleep medicine physician within the Mayo Clinic Center for Sleep Medicine.~* Patients must have moderate to severe symptoms which have been present for ≥ 3 months. Patients must endorse discomfort as part of their typical RLS/WED symptomatology.~* Patients must experience daily symptoms and must experience daily symptoms during afternoon hours (12-5 PM)~* Patients on no medications for RLS/WED, or those who have refractory symptoms despite RLS/WED medications will be enrolled. Patients on alpha-2-delta ligands (pregabalin, gabapentin) will be asked to discontinue these medications two weeks prior to starting treatments and remain off these medications throughout the study protocol.~* Informed consent to participate in this study needs to be obtained~Exclusion Criteria:~* Research authorization not provided~* Patients who are asymptomatic (either by verbal report or completion of severity scale) at time of initiation of Scrambler Therapy treatment~* Patients who have made changes in medication regimen during the 2 weeks prior to study initiation (including initiation of iron supplementation)~* Prior use of Scrambler Therapy~* Pregnant or Nursing Patients~* Patients with implantable drug delivery systems, heart stents, or metal implants (including pacemakers and defibrillators)~* Patients with history of epilepsy or other medical conditions that in the opinion of the investigators should be excluded~* Patients with skin conditions or wounds in or around the area of electrode application (lower extremities)~* Patients treated with alpha-2 delta ligands (gabapentin, pregabalin), who cannot discontinue the medications as above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Scrambler (Type: EXPERIMENTAL): All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have had at least 3 atrial fibrillation episodes within 6 months of this study~* Have failed at least one antiarrhythmic drug shown by repeated atrial fibrillation episodes~* 18 years of age or older~Exclusion Criteria:~* Have had previous ablation for atrial fibrillation~* Have take amiodarone within 6 months of this study~* Have had any heart surgery within the last 60 days~* Have had a heart attack within the last 60 days~* Females who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- THERMOCOOL® SMARTTOUCH™ Catheter (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged ≥18 years old at the time of enrollment~2. Patients who are prescribed CT-P13 or Remicade for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis prescribed according to the corresponding summary of product characteristics (SmPC and Product Monograph) as determined by the investigator~Exclusion Criteria:~1. Any reported contraindications for Inflectra according to the SmPC or Product Monograph~2. Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P13 (Type: None): biosimilar infliximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged between 18 and 45 years~* Written and signed informed consent~* Examined by a study physician before treatment~* Provided two stool samples at baseline~* Trichuris trichiura and hookworm EPG ≥ 48 and at least two Kato-Katz thick smears slides with more than one Trichuris trichiura and hookworm eggs~Exclusion Criteria:~* Pregnant or lactating and/or planning to become pregnant within three months after drug treatment~* Type 1 and/or 2 diabetes~* Psychiatric disorders~* History of ophthalmological conditions~* Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment~* Suffers from severe anaemia (Hb \< 80 g/l)~* Received anthelminthic treatment within past four weeks~* Attending other clinical trials during the study~* Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin~* Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Emodepside 5 mg (Type: EXPERIMENTAL): None
- Emodepside 10 mg (Type: EXPERIMENTAL): None
- Emodepside 15 mg (Type: EXPERIMENTAL): None
- Emodepside 20 mg (Type: EXPERIMENTAL): None
- Emodepside 25 mg (Type: EXPERIMENTAL): None
- Emodepside 30 mg (Type: EXPERIMENTAL): None
- Albendazole (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete